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Abstract
Background: The fibrinolytic system and its inhibitors play a number of roles, apart from their function in blood
haemostasis and thrombosis, namely in ovarian folliculogenesis and in ovulation. Plasminogen is converted to
active plasmin at the time of follicular rupture through a decrease in plasminogen activator inhibitor-1 (PAI-1) and
an increase in plasminogen activators. Oligo−/anovulation and follicle arrest are key characteristics of PCOS, but
studies evaluating fibrinolytic/proteolytic markers within human or animal PCOS ovaries are lacking. We aimed to
investigate and compare the expression and distribution of the plasminogen system markers in PCOS and control
ovaries.
Methods: A hyperandrogenised PCOS mouse model was used that mimics the ovarian, endocrine and metabolic
features of the human condition. Immunohistochemistry and digital image analysis were used to investigate and
compare fibrinolytic/proteolytic markers plasminogen, plasminogen/plasmin, tissue plasminogen activator, urokinase
plasminogen activator and inhibitor PAI-1 in PCOS and control ovaries. Student’s t-test was used to compare data
sets for normally distributed data and Wilcoxon-Mann Whitney test for non-normally distributed data.
Results: We noted differences in the ovarian distribution of PAI-1 that was expressed throughout the PCOS ovary,
unlike the peripheral distribution observed in control ovaries. Plasminogen was present in small follicles only in
PCOS ovaries but not in small follicles of control ovaries. When we assessed and compared PAI-1 expression within
follicles of different developmental stages we also noted significant differences for both the PCOS and control
ovaries. While we noted differences in distribution and expression within specific ovarian structures, no differences
were noted in the overall ovarian expression of markers assessed between acyclical PCOS mice and control mice at
the diestrus stage of the estrous cycle.
Conclusions: Our novel study, that comprehensively assessed the fibrinolytic/proteolytic system in the mouse
ovary, showed the expression, differential localisation and a potential role for the plasminogen system in the
physiological mouse ovary and in PCOS. Androgens may be involved in regulating expression of the ovarian
plasminogen system. Further studies evaluating these markers at different time-points of ovulation may help to
further clarify both physiological and potential pathological actions these markers play in ovulatory processes
distorted in PCOS.
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Background
Polycystic Ovary Syndrome (PCOS) is a common condi-
tion, affecting 12–18% of reproductive aged women and
is diagnosed based on ovulatory and menstrual disturb-
ance, hyperandrogenism and polycystic appearance of
ovaries on ultrasound [1–7]. Women with PCOS have
increased risk factors for cardiovascular disease (CVD)
and venous thromboembolism (VTE) likely relating to
the aberrant metabolic features and elevated BMI, fre-
quently present in PCOS, but also to the recently identi-
fied abnormalities in the haemostatic and fibrinolytic
systems [8, 9]. A mild to moderate hypofibrinolytic state
is present in women with PCOS, relating to increased
plasminogen activator inhibitor 1 (PAI-1) that prevents
conversion of the pro-enzyme plasminogen to its active
form of plasmin [9]. The fibrinolytic system markers and
its inhibitors play a number of roles, apart from their
function in blood haemostasis and thrombosis, namely
in ovulation and folliculogenesis. In animal models it
was shown that follicle rupture is achieved following an
increase in plasminogen activator/s (PA) and a decrease
in fibrinolytic inhibitor PAI-1 [10]. Plasmin has also
been detected in the ovary of porcine models at the time
of or just before rupture of the ovarian follicle [10]. This
suggests that plasminogen is converted to its functional
form of plasmin at the time of follicular rupture. It was
also noted that immediately prior to ovulation PAI-1
levels are at their highest in the centre of the ovary,
where immature follicles reside, whereas PA tissue plas-
minogen activator (tPA) is highest at the surface, where
preovulatory follicles are localised [11]. A review by Liu
et al concluded that the serine protease tPA as well as
inhibitor PAI-1 play the most significant role in ovula-
tion processes but also have a function in oocyte matur-
ation [12]. These researchers also noted interspecies
differences in expression of different PA as well as a
cell-specific and time-dependent response of the ovarian
expression of both tPA and PAI-1. To our knowledge,
there have been no published studies that have evaluated
the fibrinolytic/proteolytic system in PCOS mouse
models. However in a study by Devin et al, using trans-
genic female mice that constitutively secrete a stable
variant of active human PAI-1, it was observed that
these mice contain many large cystic structures within
their ovaries and had plasma testosterone levels nearly
twice as high as control mice [11]. They concluded that
overexpression of PAI-1 promotes the development of
polycystic ovarian changes, however they did not evalu-
ate metabolic or fibrinolytic markers in these mice. Ma
et al on the other hand showed that mice which lacked
PAI-1, unlike their wild type counterparts, did not de-
velop high fat/high carbohydrate diet-induced obesity
and insulin resistance, which are key clinical features of
PCOS [13].
Physiological studies in humans have also identified
the presence of tPA and PAI-1 in human ovaries [14–16]
and only few studies have been carried out evaluating fi-
brinolytic/proteolytic system markers and inhibitors
within human PCOS ovaries. Ambekar et al performed
proteomic analysis of ovarian follicular fluid from
women with PCOS compared to that of healthy
aged-matched non-PCOS women. They found that plas-
minogen is degraded within the follicular fluid of ovaries
in women with PCOS compared to non-PCOS women
[17]. Quantitation of overexpressing proteins identified
the upregulation of SERPINA 1, a plasminogen activator
inhibitor in the follicular fluid of ovaries of females with
PCOS that can result in reduced plasmin levels. Atiomo
et al found that PAI-1 was expressed in both the granu-
losa and theca cell compartments of PCOS and
non-PCOS human ovaries and while there was overall
more PAI-1 detected around the follicles of polycystic
ovaries this did not reach statistical significance when
compared to control ovaries [16]. While these studies
presented interesting findings, they both had small sam-
ple sizes and in the latter study [16] samples were taken
from women at various stages of the menstrual cycle. In
contrast, Devin et al found PAI-1 to be prevalent in all
five of the human PCOS ovary specimens, localised to
the granulosa cells lining cystic structures and to atretic
follicles, but none of the non-PCOS ovaries demon-
strated significant PAI-1 expression [11].
Oligo−/anovulation and follicle arrest are key charac-
teristics of PCOS, which are associated with infertility in
this group of women, with the exact mechanism/s
remaining unclear [5–7, 18, 19]. While PAI-1 is believed
to play a physiological role within the ovary in prevent-
ing ovulation of immature central follicles, persistent
elevation of this fibrinolytic/proteolytic inhibitor, as is
noted in the plasma of women with PCOS, may poten-
tially contribute to a lack of ovulation. Plasminogen acti-
vator inhibitor-1 may prevent follicular wall breakdown
of more mature preovulatory follicles and may contrib-
ute to the ovarian architecture currently observed in the
ovaries of women with PCOS.
In this context, we aimed to investigate and compare
the expression and distribution of fibrinolytic/proteolytic
markers: plasminogen, plasmin, PA: tPA and urokinase
plasminogen activator (uPA) and inhibitor PAI-1 in con-
trol and PCOS ovaries. We used a PCOS mouse model
treated with dihydrotestosterone (DHT) that display ex-
tensive ovarian, endocrine and metabolic features of
humans affected by PCOS including oligo- or anovulation,
irregular menstrual cycles, polycystic ovaries, obesity and
dislipidaemia [20]. We hypothesized that all fibrinolytic/
proteolytic markers investigated in this study will be
expressed in both the PCOS and control mice ovaries,
highlighting their potential role in either physiological or
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pathological ovulation (and/or other ovarian functions),
however they will vary in their intensity and distribution
within the tissues. In general, PAI-1 expression will be ele-
vated in the PCOS mouse ovaries compared to that of
controls and this marker will be distributed throughout
the tissue, while in controls it will be localised mainly cen-
trally. The ovarian expression and distribution of PA may
be similar, but differences may be noted for plasmin/plas-
minogen in PCOS and control mice. We further hypothe-
sized there will be a gradual increase in PAI-1 expression
in both control and PCOS ovaries as follicles develop from
small through to antral stages, however a decreased ex-
pression of this marker will be noted in preovulatory folli-
cles of normal controls, though not so in the same
follicles of PCOS ovaries.
Methods
Mice
In this study all mice had a wild-type androgen receptor
(AR) genotype and were taken from a colony used to
generate AR-knockout mice [21, 22]. This colony has
been backcrossed onto a C57BL/6J background for at
least 10 generations prior to use in experiments. Litter-
mate controls were used. Mice were fed a standard chow
diet (2018S Teklad Global 18% Protein Rodent Diet,
ENVIGO, USA), and were maintained under standard
housing conditions (ad libitum access to food and water
in a temperature and humidity controlled, 12-h light
cycle environment) at the ANZAC Research Institute
[Concord, Australia] [20]. All procedures were per-
formed under ketamine/xylazine anaesthesia. All proce-
dures were approved by the Sydney Local Health
District Animal Welfare Committee within NHMRC
guidelines for animal experimentation [20].
Development of PCOS mouse model
PCOS was induced by postnatal androgenization as pre-
viously described [20]. Briefly, 21-day old female mice
were implanted sc with either a blank (controls) 1 cm SI-
LASTIC brand implant (id, 1.47 mm; od, 1.95 mm, Dow
Corning Corp, catalog no. 508–006), or an implant con-
taining ~ 10mg DHT. Mice were collected after 13
weeks of drug administration (n = 8 control mice; n = 9
DHT mice) when the mice were 16 weeks of age [20].
Assessment of estrous cycle
The stage of the estrous cycle was identified in the mice
on a daily basis using light microscopy examination of
vaginal epithelial cell smears, as previously described
[20]. The stage of the estrous cycle was determined
based on the presence or absence of leukocytes, corni-
fied epithelial cells, and nucleated epithelial cells. The
proestrous stage was characterized by the presence of
mostly nucleated and some cornified epithelial cells; at
the estrous stage mostly cornified epithelial cells were
present; at the metestrus stage both cornified epithelial
cells and leukocytes were present; and at the diestrus
stage primarily leukocytes were visible [20]. Control
mice were collected at the diestrus stage of the estrous
cycle and stage of cycle was unascertainable for PCOS
mice as these mice did not cycle.
Collection and processing of ovaries
The present study was completed using bio-banked
ovarian tissue samples from control and PCOS mice
from our prior study [20]. Data on body weight/fat,
metabolic (cholesterol, triglycerides, insulin tolerance
test), hormonal (FSH, LH, testosterone) and reproduct-
ive/ovarian parameters have been previously published
[20]. Dissected ovaries were weighed and fixed in 4%
paraformaldehyde at 4 °C overnight and then stored in
70% alcohol until histological processing [20]. Ovaries
were then dehydrated in alcohols, cleared in xylene and
embedded in paraffin. A total of n = 6 control ovaries
and n = 6 PCOS ovaries (out of the 8 ovaries available
for control mice and 9 ovaries for PCOS/DHT mice)
were assessed in the present study. Paraffin-wax embed-
ded ovarian tissue from the DHT-induced PCOS and
control mice was sectioned at 4 μm thickness and
mounted onto 3-aininopropyltricttiosilane-coated glass
slides, then dried overnight in a 50 °C incubator or incu-
bated at 60 °C for 2 h.
Expression of PAI-1, tPA, uPA, plasminogen and plasmin
by immunohistochemistry
We used immunohistochemical detection of PAI-1, tPA,
uPA, plasminogen/plasmin and plasminogen in sec-
tioned tissue of both PCOS and control mice. We were
unable to identify an antibody to plasmin alone. Immu-
nohistochemistry (IHC) was initially performed on sec-
tions of normal mouse tissue known to contain PAI-1,
tPA, uPA, plasmin and plasminogen; namely liver for
PAI-1, plasminogen/plasmin and plasminogen only,
brain for tPA and kidney for uPA (positive control tis-
sues) to determine ideal working conditions. A negative
control (to test the effects of non-specific binding of the
secondary antibody) was also tested with each marker by
omitting the primary antibody. PCOS and control ovar-
ian mouse sections were stained simultaneously for each
marker in order to avoid variability due to technical is-
sues. Commercially available primary antibodies that
have been shown to work in IHC applications on
paraffin-embedded sections (IHC-P) were used for all
markers with the exception of the plasminogen only
antibody that was shown to work in immunocytochem-
istry techniques and it was hypothesized that it would
also work in IHC. We confirmed this through initial
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IHC staining of positive and negative controls followed
by PCOS and control ovarian tissue.
Slides were deparaffinised in xylene and rehydrated in
graded alcohol. Antigen retrieval was performed in a
pressure cooker containing sodium citrate buffer (pH
6.0) for 20 min for all markers except for PAI-1 where
only 10 min incubation was used and uPA where Tris
EDTA buffer (pH 9.0) was used instead of sodium cit-
rate. Endogenous peroxide activity was quenched by 3%
H2O2 in water for 15 min. Non-specific binding was re-
duced using 1% normal goat serum (ABC Kit VECTA-
SIN). The slides were incubated with the primary
antibody at room temperature for either 90 min for
PAI-1 (rabbit polyclonal antibody to mouse PAI-1,
ABCAM: ab28207) (1:250), uPA (rabbit monoclonal anti-
body to mouse uPA, ABCAM: ab133563) (1:150), tPA
(rabbit polyclonal antibody to mouse tPA, ABCAM:
ab28208) (1:200) and plasminogen/plasmin antibodies
(rabbit polyclonal antibody to mouse plasminogen/plas-
min, Novus Biologicals: NBP2–19859) (1:300) or over-
night at 4 °C for the plasminogen only antibody (rabbit
polyclonal antibody to mouse plasminogen, Novus Biolog-
icals: NB300–544) (1:100). Slides were then incubated
with the secondary antibody (ABC Kit VECTASIN
Anti-rabbit IgG biotinylated, affinity purified
anti-immunoglobulin) for 30min for all antibodies except
tPA where this step was omitted (as the primary antibody
to tPA was biotinylated). 3,3′-diaminobenzidene, DAB
(Vector ImmPACT DAB) was used as a chromagen for 2–
3min and haematoxylin was used for counterstaining.
Follicular classification and enumeration
When describing the expression/distribution of fibrino-
lytic/proteolytic markers in murine PCOS and control
whole ovaries (Table 1), follicles were classified as either
small or large. The small follicles described typically rep-
resented primordial and primary follicles while the large
follicles included secondary and Graafian follicles. The
follicle classification system used for analyzing/quantify-
ing individual sized follicles for PAI-1 expression in
PCOS and control ovaries (Table 3) was based on the
system used by Myers et al [23]. Briefly, primordial folli-
cles consisted of an oocyte surrounded by flattened
granulosa cells; primary follicles consisted of an oocyte
surrounded by one layer of cuboidal granulosa cells;
small preantral follicles contained an oocyte with 1.5–2
layers of cuboidal granulosa cells; large preantral follicles
were classified by having an oocyte surrounded by more
than two and up to five layers of cuboidal granulosa
cells; small antral follicles contained an oocyte sur-
rounded with more than five layers of cuboidal granu-
losa cells, and/or one or two small areas of follicular
fluid whereas large antral follicles contained a single
large antral cavity, and preovulatory follicles possessed a
single large antrum and an oocyte surrounded by cumu-
lus cells at the end of a stalk of mural granulosa cells
[21, 23]. These follicles were further grouped into: small
follicles (primordial and primary follicles), medium or
preantral follicles (small and large preantral follicles),
large or antral follicles (small and large antral follicles)
and preovulatory follicles.
Image analysis
Sections were scanned into digital format using an Olym-
pus Microscope and Slide Scanner (Olympus VS-ASW
2.9, Tokyo, Japan) keeping the (light) exposure time con-
stant for all slides (930 μs). Sections were examined and
the distribution of staining in the ovary (PCOS or control)
for each marker was determined by an experienced oper-
ator (DP) blinded to the identity of the ovarian sample/tis-
sue type (Table 1). Digital image analysis and processing
of each scanned slide was performed next using the Olym-
pus cellSens software (Olympus cellSens Dimension Desk-
top 1.16, Tokyo, Japan), ‘Count & Measure’ functionality
that allows selection of a region of interest and cell/region
counting capabilities. Intensity analysis was used to deter-
mine intensity of (brown) staining in each of the sections.
Positive thresholds (of intensity of staining) were set for
each marker on the positive control tissues. The positive
thresholds for each marker were then applied to the nega-
tive control tissues to ensure negative/no detection of
staining for the thresholds set. Mouse PCOS and control
ovarian tissues were evaluated with the set positive inten-
sity threshold of staining of each marker. Initially the
whole ovary for both PCOS and controls was selected as
the region of interest (ROI). Overall ovarian staining (Sum
Area, μm2), percentage of ovarian staining (Area Fraction
ROI, %) and intensity of this staining (Mean Colour Inten-
sity) was investigated and compared in PCOS and control
ovaries for each plasminogen system marker (Table 2).
Overall follicular staining, percentage of follicular staining
and intensity of this staining was also investigated and
compared for PAI-1 within PCOS and control ovarian fol-
licles in small follicles, preantral follicles, antral follicles
and preovulatory follicles (Table 3). Image analysis and
processing was performed by an operator (GB) blinded to
the identity of the ovarian sample/tissue type (ie PCOS or
controls).
Statistical analysis
Image analysis parameters are presented as mean values
± SD or mean values ±SEM. Statistical analysis was per-
formed using Stata15 (Statacorp, College Station, TX)
and SPSS for Windows 22.0 software (SPSS, Inc., Chi-
cago, USA) with statistical significance *p ≤ 0.05. Data
was assessed for normality and log transformed where
appropriate. Results are presented for a total of 12 mice
(n = 6 control mice; n = 6 DHT-induced PCOS mice).
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One ovarian section was selected and assessed from each
mouse (i.e. one section per mouse) for every plasmino-
gen system marker evaluated (i.e. 6 ovarian sections
from all control mice and 6 ovarian sections from all
DHT-induced PCOS mice for PAI-1; alike for the
remaining 4 markers). Differences between PCOS and con-
trol ovarian IHC staining for all markers were assessed
using Student’s t-test for normally distributed data and the
Wilcoxon-Mann Whitney test for non-normally distributed
data. Similarly, Student’s t-test was used to compare PAI-1
IHC staining between different sized follicles in PCOS and
control ovaries. Further analysis to examine differences in
PCOS and controls on the outcomes, t-tests adjusting for
potential clustering were performed and Intracluster corre-
lations (ICC) reported.
To further examine the association between the main
outcomes of interest using PCOS status as a covariate
adjusted by follicular stage, linear mixed models were
used. Potential interaction between PCOS status and fol-
licular size on the outcomes were also tested using the
above mentioned statistical method.
Results
Ovarian morphology
Ovaries from DHT-induced PCOS female mice exhibited
the classic polycystic ovary morphology with a complete
absence of corpora lutea, indicating anovulation. Control
ovaries, on the other hand, displayed numerous corpora
lutea consistent with recent ovulation (Fig. 1). Moreover,
follicles with an atretic cyst-like appearance were observed
in ovaries from DHT treated females, but not in control
ovaries (Fig. 1).
Localisation of fibrinolytic/proteolytic markers in murine
PCOS and control ovaries
Expression and localization of PAI-1, tPA, uPA, plas-
minogen/plasmin and plasminogen only in experimental
mouse ovaries was investigated.
Expression of PAI-1 in mouse PCOS and control ovaries
In the non-PCOS mouse (control) ovaries, PAI-1 was
predominantly found in the granulosa cells (GC), with
greatest expression present in large follicles located mainly
in the periphery of the ovary (Table 1 and Fig. 2 a & c).
PAI-1 was also observed in the follicular fluid (FF) and in
the stroma with only scant amounts detected in the small
(central) follicles and theca cells (TC) (Fig. 2 a & c). In the
PCOS mouse ovaries, PAI-1 was expressed throughout
the ovary. Similar to controls, PAI-1 was also abundant in
the GC, and noted in the FF, stroma and large follicles
with low amounts observed in the small follicles and TC
of PCOS ovaries (Table 1 and Fig. 2 b & d).
Expression of plasminogen activators: uPA and tPA in
mouse PCOS and control ovaries
Urokinase plasminogen activator (uPA) was present
mainly in the periphery of control ovaries as well as
in the stroma and GC (Table 1 and Fig. 3 Ai & Aiii).
This marker was mainly detected in the large follicles
however it was observed in some small follicles but
only in scant amounts in the TC and FF (Fig. 3 Aiii).
A similar pattern was observed in the PCOS ovaries,
where uPA was predominantly observed in the per-
iphery; and was abundant in the GC, as well as in
the stroma (mainly in the centre of the ovary), large
and small follicles with only small amounts observed
in the TC and FF (Table 1 and Fig. 3 Aii & Aiv).
The other PA, tPA, was not observed in either the
PCOS or control ovaries (Table 1 and Fig. 3 b), only
light staining was observed in the centre of the con-
trol ovaries and the stroma, small follicles and GC
(Fig. 3 Bi & Biii).
Expression of plasminogen/plasmin or plasminogen alone
in mouse PCOS and control ovaries
As there was no specific plasmin antibody that could
be used for IHC staining we used one which detected
both plasminogen/plasmin as well as one that only
Fig. 1 Histological images of normal (control) versus PCOS mouse ovaries. Images demonstrate (a) normal mice (controls) ovarian features in the
mouse model used including the presence of a corpora luteal (CL) versus no such feature in the (b) PCOS mice ovary where mice are acyclical.
Several (but not all) representative CL shown in the image. The scale bar represents 500 μm for A and 200 μm for B
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detected plasminogen in this study. Differences in the
staining between these two antibodies would most
likely be due to that of plasmin alone. Plasminogen/
plasmin (NBP2–19859) was present mainly in periph-
eral follicles of control ovaries, with less pronounced
staining observed in central (small) follicles (Table 1
and Fig. 4 Ai & Aiii). It was present in abundance in
GC and FF and also in the stroma. Weak staining
was observed in blood vessels as well as in the an-
trum and TC of control ovaries (Fig. 4 Ai & Aiii). In
PCOS ovaries plasminogen/plasmin was mainly ob-
served in the periphery with a similar pattern of distribu-
tion in the GC, FF, stroma, large follicles, antrum, blood
vessels and TC compared to controls (Table 1 and Fig. 4
Aii & Aiv).
The plasminogen antibody NB300–544 detects only
plasminogen but not plasmin. Plasminogen was detected
throughout control ovaries, mainly present in the GC
and FF (Table 1 and Fig. 4 Bi & Biii). It was also ob-
served in large follicles and sometimes seen in TC while
low levels were observed in small follicles, the stroma,
antrum and cumulus oophorus of control ovaries (Fig. 4
Bi & Biii). In the PCOS ovaries plasminogen was abun-
dantly present in the FF, and was observed in the TC
and GC, as well as in small and large follicles, with low
levels in the stroma (Fig. 4 Bii & Biv).
Table 1 Expression and distribution of the plasminogen system markers in control and PCOS mice ovaries
Granulosa cells Theca cells Large follicles Small follicles General distribution
Con PCOS Con PCOS Con PCOS Con PCOS Con PCOS
PAI-1 + + – – + + – – P T
tPA – – – – – – – – A A
uPA + + – – + + + + P P
Plasminogen/Plasmin + + – – + + – – P P
Plasminogen only + + +/− + + + – + T T
‘+’ = expression of marker; ‘-’ =marker absent or in low levels. PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator; uPA, urokinase
plasminogen activator; Con, controls; P, peripheral; C, central; T, throughout; A, absent. The small follicles described typically represent primordial and primary
follicles while the large follicles include secondary and Graafian follicles
Fig. 2 Expression of PAI-1 in normal and PCOS mouse ovaries. Left: Representative histological images are from (a, c) normal (control) or (b, d)
PCOS ovaries stained with an anti-PAI antibody. The scale bar represents 500 μm for A, 200 μm for B and 100 μm for C & D. Right: Top: Negative
control on mouse liver and Bottom: Graphical representation comparing the percentage of ovarian staining (Area Fraction ROI) for PAI-1 between
normal and PCOS ovaries for 6 replicates of each experimental group (mean ± SD)
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Comparisons of fibrinolytic/proteolytic markers in murine
PCOS versus control ovaries expression using
immunohistochemistry
It is well accepted that human PCOS ovaries are generally
larger in size and volume compared to non-PCOS ovaries.
When performing initial image analysis of the whole
ovary, we noted a significant difference in the average
ovarian sizes between PCOS and control mice as reflected
in the average area ROI (p = 0.01). As a result of this we
investigated the % staining of the ovaries from control and
PCOS mice (Area Fraction ROI) of each marker. Overall,
we did not observe any significant difference in the stain-
ing for PAI-1, tPA, uPA, plasminogen/plasmin or plas-
minogen evaluated for either mean total area of IHC
staining (Sum Area), percentage of staining (Area Fraction
ROI) or average intensity of staining (Mean Colour
Fig. 3 Expression of plasminogen activators uPA and tPA in normal and PCOS mouse ovaries. Left: Top: (a) uPA and Bottom: (b) tPA.
Representative histological images are from normal (control) (Ai, Aiii, Bi, Biii) or PCOS ovaries (Aii, Aiv, Bii, Biv) stained with an (a) anti-uPA or (b)
anti-tPA antibody. The scale bar represents 500 μm for Ai, Aii, Bi & Bii, 200 μm for Aiii & Biv and 100 μm for Aiv & Biii. Right: Top: Negative control
for uPA on mouse kidney and graphical representation comparing the percentage of ovarian staining (Area Fraction ROI) for uPA between
normal and PCOS ovaries for 6 replicates of each experimental group (mean ± SD) and Bottom: Negative control for tPA on mouse brain and
graphical representation comparing the percentage of ovarian staining (Area Fraction ROI) for tPA between normal and PCOS ovaries for 6
replicates of each experimental group (mean ± SD)
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Intensity Value) of whole ovaries between PCOS and con-
trols (Table 2; p > 0.05).
Comparison of PAI-1 expression in ovarian follicles of
PCOS versus control mice using immunohistochemistry
When we analysed individual sized follicles for PAI-1
expression in PCOS and control ovaries, there was a
statistically significant increase in this marker as the
follicles developed from small (primordial and pri-
mary) through to preantral (medium) follicles in both
the control (p = 0.03 for % of follicular staining/Area
Fraction ROI; p = 0.02 for Mean Colour Intensity of
follicles) and in PCOS ovaries (p = 0.01 for % of fol-
licular staining; p = 0.009 for Mean Colour Intensity
of follicles) (Table 3 and Fig. 5 a). A fall in the PAI-1
concentration was then noted from preantral to antral
Fig. 4 Expression of plasminogen/plasmin (NBP2–19859) or plasminogen alone (NB300–544) in normal and PCOS mouse ovaries. Left: Top: (a)
plasminogen/plasmin (NBP2–19859) and Bottom: (b) plasminogen alone (NB300–544). Representative histological images are from normal
(control) (Ai, Aiii, Bi, Biii) or PCOS ovaries (Aii, Aiv, Bii, Biv) stained with an (a) anti-plasminogen/plasmin or (b) an anti-plasminogen only antibody.
The scale bar represents 500 μm for Ai, Aii, Bi & Bii and 100 μm for Aiii, Aiv, Biii & Biv. Right: Top: Negative control for plasminogen/plasmin on
mouse liver; Middle: Graphical representation comparing the percentage of ovarian staining (Area Fraction ROI) for plasminogen/plasmin and
plasminogen alone between normal and PCOS ovaries for 6 replicates of each experimental group (mean ± SD) and Bottom: Negative control for
plasminogen alone on mouse liver
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(large) follicles in control ovaries (p = 0.009 for % of
follicular staining; p = 0.004 for Mean Colour Intensity
of follicles) though in PCOS ovaries the drop in this
marker in these same follicles was not significant/of
borderline significance (p = 0.09 for Mean Colour In-
tensity of follicles). A downward trend was noted
from antral to preovulatory follicles in control ovaries
(% of follicular staining 14.1 ± 11.0 in antral versus
0.24 in pre-ovulatory follicles), however an increase in
PAI-1 concentration in these same follicles was ob-
served in PCOS ovaries (% of follicular staining 14.6
± 14.6 in antral versus 23.3 ± 12.9 in preovulatory fol-
licles) (Table 3 and Fig. 5a), though a statistical ana-
lysis could not be completed due to the low numbers
of preovulatory follicles. No significant difference was
noted in the PAI-1 follicular concentrations in small,
preantral and antral follicles in control versus PCOS
ovaries (p > 0.05). Statistical evaluation could not be
made between PCOS and controls in preovulatory fol-
licles due to the low sample size.
When we grouped the antral and preovulatory follicles
together (to increase sample size/follicle numbers), we
noted a statistically significant difference when comparing
medium sized follicles (preantral) and grouped antral and
preovulatory follicles for % of follicular staining for the
control ovaries (p = 0.02) and no significance difference in
PCOS (p = 0.11) (Table 3 and Fig. 5 b). Figure 6 displays
the changes in PAI-1 expression (%) within different
follicular sizes/stages for PCOS and control ovarian folli-
cles, noting similar expression/trends in small through to
large follicles for the 2 experimental groups however dif-
ferential expression/trend for the grouped antral and pre-
ovulatory stage.
Further analysis to examine differences in PCOS and
controls on the outcomes indicated that there were no
statistically significant differences between PCOS and
controls for the three outcomes (Mean Total Area,
Percentage of Staining and Average Intensity of Staining)
categorized by follicular stage. A statistical analysis to
test the association between the outcomes of interest
Table 2 Comparisons of whole ovarian IHC staining of markers assessed in PCOS and control mice ovaries
Marker PCOS/ Controls N Mean Total Area (Sum Area) (μm2)(× 103) Percentage of Staining




PAI-1 Controls 6 281 ± 264 7.86 ± 5.96 178.27 ± 6.79
PCOS 6 323 ± 266 13.90 ± 10.57 177.07 ± 8.40
tPA Controls 6 17 ± 22 0.63 ± 0.79 172.90 ± 6.02
PCOS 6 8 ± 10 0.29 ± 0.38 169.73 ± 4.20
uPA Controls 6 227 ± 174 7.61 ± 5.72 164.58 ± 6.57
PCOS 6 155 ± 125 6.86 ± 5.37 163.43 ± 4.04
Plasminogen/Plasmin NBP2–19859 Controls 6 271 ± 183 7.21 ± 4.09 178.95 ± 3.18
PCOS 6 193 ± 79 8.64 ± 3.53 180.70 ± 6.25
Plasminogen NB300–544 Controls 6 1147 ± 1092 38.93 ± 23.14 165.16 ± 5.09
PCOS 6 936 ± 646 41.10 ± 23.38 162.72 ± 8.75
Mean ± SD are represented for all values. PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen activator; uPA, urokinase plasminogen activator; ROI,
region of interest; N = number of mice ovarian sections or number of mice evaluated (one ovarian section per mouse)








P-value ICC* Percentage of
Staining (Area
fraction ROI) (%)






Controls 50 186.54 ± 338.8 14.6 ± 14.9 165.3 ± 43.4
PCOS 60 122.7 ± 221.4 0.48 0.17 13.8 ± 18.9 0.92 0.52 155.3 ± 53.4 0.32 < 0.01
Preantral Controls 44 1505.6 ± 1608.2 19.8 ± 16.4 178.8 ± 7.3
PCOS 41 1836.2 ± 2356.4 0.71 0.36 19.4 ± 19.9 0.96 0.61 177.5 ± 11.8 0.82 0.73
Antral Controls 49 9507 ± 9242 14.1 ± 11.0 175.3 ± 7.23
PCOS 53 9092 ± 13,318 0.93 0.41 14.6 ± 14.6 0.94 0.56 171.3 ± 25.8 0.41 0.05
Antral &
Preovulatory
Controls 50 9326 ± 9236 13.9 ± 11.0 175.5 ± 7.41
PCOS 56 10,132 ± 13,950 0.46 0 15.1 ± 14.5 0.56 0.13 171.2 ± 25.2 0.56 0.92
*ICC = Intra Class Correlation; ROI = region of interest
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and the covariates PCOS status and follicular stage re-
vealed no significant differences between PCOS and
controls however, there were significant differences be-
tween follicular stage with small as the reference cat-
egory. The test for potential interactions between PCOS
status and follicular stage on the outcomes were statisti-
cally non-significant (Tables 3 and 4).
Discussion
To our knowledge, this is the first study that has com-
prehensively looked at the expression and distribution of
fibrinolytic/proteolytic markers and the plasminogen
system in a PCOS model. Our novel findings showed a
lack of tPA expression in the ovaries of both control and
PCOS mice, however the presence and potential role of
the fibrinolytic/proteolytic markers PAI-1, uPA, plas-
minogen and plasminogen/plasmin were demonstrated
in the physiological and pathological ovaries of healthy
controls and PCOS mice, respectively.
In the control ovary PAI-1 was predominantly ob-
served in the GC, present also in large follicles mainly in
the periphery of the ovary, in FF and in the stroma. In
the rat, the TC are predominantly responsible for the
production of PAI-1 with no synthesis from the oocyte
(into the FF); the GC may also express PAI-1 however
this will correlate with the stage of the ovulation cycle to
ensure appropriate proteolytic (plasmin) activity with
each stage [12, 24]. In our study, at the diestrus stage of
the cycle, the GC seem to be involved in the production
of PAI-1 in mice. In pigs and rats the distribution of
PAI-1 immediately prior to ovulation was lower in per-
ipheral/large follicles and highest in small/central folli-
cles to assist in ovulation and follicular wall rupture of
mature follicles [11, 25]. As the control mice in our
Fig. 5 Changes in PAI-1 follicular staining as follicles develop in PCOS and control mouse ovaries. Percentage of PAI-1 follicular staining (Area
Fraction ROI) from (a) small through to preovulatory follicles (between 41 and 59 replicates for each follicle type/size in each experimental group,
with the exception of preovulatory follicles with only 1–3 replicates in each experimental group) and (b) with grouped data for antral and
preovulatory follicles. Pre-ov = Preovulatory. Error bars represent SD
Fig. 6 Comparison of PAI-1 follicular expression between PCOS and controls within different follicular sizes/stages. Comparison of PAI-1 follicular
expression (Object Area ROI, %) between PCOS and controls within different follicular sizes/stages, from small through to combined antral and
preovulatory follicles. Between 41 and 59 replicates for each follicle type/size in each experimental group. Error bars represent SEM
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study were in the diestrus stage of the cycle a different
pattern was noted, which may be related to differential
proteolytic needs at this stage of the cycle (i.e. less needs
for a greater plasmin activity) or the differences noted
may be related to inter-species differences. In the PCOS
ovary PAI-1 was found throughout the ovary, unlike the
peripheral distribution observed in the controls. It was
abundant in the GC, noted in FF, stroma and large folli-
cles. This pattern of distribution in the PCOS mice may
relate to their acyclical nature and the presence of pre-
dominantly ‘arrested’ follicles that do not go on to ovu-
late. As PAI-1 is present in follicles approaching
ovulation, and as its levels drop immediately prior to
ovulation in the preovulatory follicles, an even ovarian
distribution of PAI-1 in the PCOS mice may relate to
the presence of follicles in various stages of development
along with a reduced number of preovulatory follicles.
Our results are similar to that reported by Devin et al
who assessed transgenic PAI-1 overexpressing mice that
went on to develop multicystic ovaries, in contrast to
the wild-type controls [11]. They observed that PAI-1
was abundant throughout the ovaries of the transgenic
mice, and was expressed strongly in the GC of develop-
ing follicles (and in the thickened tunica, cyst lining and
hypertrophied theca) [11]. Studies in humans also ob-
served the presence of PAI-1 in the granulosa cell com-
partment but also in the TC in both non-PCOS and
PCOS ovaries [16]. Devin et al observed PAI-1 to be
localised only on the GC lining cystic structures and in
atretic follicles of females with PCOS and was absent/
observed in scant amounts in human controls [11]. Nei-
ther of these research groups however stated the stage of
the oestrous cycle of control women and confirmation
of elevated androgen levels for all PCOS participants
was not undertaken in the study by Atiomo et al [16].
When analysing and quantifying marker expression
using image analysis, we initially selected the whole
ovary, as the region of interest for all five markers. This
is as a result of the lack of published data assessing the
plasminogen system in the PCOS ovary. When we com-
pared the mean total amount of overall ovarian IHC
staining (Sum Area), the mean total percentage of
Table 4 Linear mixed models noting association between the main outcomes using PCOS status as covariate adjusted by follicular
stage
Primary Outcomes β (95% CI) P-Value p-value (interaction)*
Mean Total Area
Risk Factors
PCOS 514 (− 2821 to 3849) 0.76 NS
Follicular type
small Ref
medium 1384 (−500 to 3269) 0.15
large 10,765 (8774 to 12,757) > 0.001
large & preovulatory 6974 (4008 to 9941) > 0.001
Percentage of Staining
Risk Factors
PCOS 0.28 (−14.1 to 14.0) 0.96 NS
Follicular type
small Ref
medium 5.98 (2.75 to 9.22) < 0.001
large −0.37 (−3.82 to 3.07) 0.83
large & preovulatory 4.5 (−0.70 to 9.78) 0.09
Average Intensity of Staining
Risk Factors
PCOS −5.4 (−12.74 to 1.9) 0.15 NS
Follicular type
small Ref
medium 18.02 (8.9 to 27) > 0.001
large 12.05 (2.7 to 21.4) 0.25
large & preovulatory −4.4 (−30.9 to 22.0) 0.74
*Test of possible interaction between PCOS status and follicular size on the three outcomes. NS = not significant
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ovarian staining (Area Fraction ROI) and the average in-
tensity of this staining (Mean Colour Intensity Value) for
PAI-1 in PCOS and controls, we found no statistically
significant differences between the two groups. This
however does not exclude a potential difference in the
expression of the marker between PCOS and controls
within specific ovarian structures (ie follicles, cells, etc)
or at other time-points of ovulation. Our results are
however consistent with the study by Atiomo et at
who also noted overall more PAI-1 was detected in
PCOS ovaries but this was not statistically different
to controls [16].
We then further investigated and quantified PAI-1
concentrations in developing ovarian follicles in both ex-
perimental models. As hypothesized, we found a statisti-
cally significant increase in PAI-1 as follicles developed
from small through to preantral follicles in both control
and PCOS ovaries. This increased expression may be ne-
cessary to ensure these follicles remain intact and no
premature follicular (wall) rupture takes place. A reduc-
tion in PAI-1 expression was observed in both mouse
models as follicles developed from preantral through to
antral stages, though this was only borderline statistically
significant in PCOS ovaries. PAI-1 expression continued
to fall in controls from antral through to preovulatory
follicles, likely to ensure a high plasmin activity required
for follicular rupture immediately preceding ovulation.
Conversely, an increase in PAI-1 was noted in PCOS
ovaries as follicles developed through these same ovula-
tory sizes/stages. This may in turn prevent conversion of
plasminogen to active plasmin, following from an inhib-
ition of PA by PAI-1, and ultimately a lack of follicular
wall breakdown and ovulation in the pathological PCOS
ovary. As a low sample size of preovulatory follicles were
assessed in PCOS and control ovaries (due to the low
numbers of such follicles at the diestrus stage of the
cycle in the latter and owing to the acyclical nature of
PCOS ovaries in the former) we performed further stat-
istical analyses on grouped data. We also noted a statisti-
cally significant difference in PAI-1 concentrations in
medium (preantral) versus grouped antral and preovula-
tory follicles of controls though not significant in these
same follicles in PCOS ovaries. Evaluating and compar-
ing the trends between PCOS and control ovaries in
PAI-1 expression (Object Area ROI, %) as follicles devel-
oped, similar expression/trends were noted in small
through to large follicles for the 2 experimental groups
however differential expression/trend for the grouped
antral and preovulatory size/stage was observed; PCOS
mice noted an increased trend in the latter ovarian folli-
cles/stage while a predominantly downward trend was
observed for the control mice (Fig. 6).
There were similar patterns of expression and distribu-
tion of the plasminogen activator uPA in PCOS and
controls with the marker being predominantly present in
the periphery of the ovary and in the GC and stroma of
both control and PCOS ovaries. Image analyses that
quantified this PA did not reveal any significant differ-
ences in overall ovarian expression between PCOS and
controls. The other PA, tPA was not expressed in either
of the assessed mouse models. Here we present novel
findings on the presence and distribution of uPA in the
PCOS mouse ovary, and demonstrate the expression and
potential role of this plasminogen activator in normal
physiological folliculogenesis and in early ovarian tissue
remodeling processes (at the diestrus stage of the cycle)
in normal mouse ovaries; we also demonstrate no dis-
torted presence/distribution in PCOS. Under normal
physiological function, uPA (and other PA) are thought
to play a role in the formation and maintenance of the
corpus luteum and tissue remodeling processes
post-ovulation in rhesus monkeys and may also do so in
mice [11, 25, 26]. A lack of tPA involvement in both
mouse models may relate to interspecies differences (in
expression of PA) or may relate to the stage of the es-
trous cycle when mice were assessed.
A similar pattern of distribution of the plasminogen
antibody used in the study (that does not distinguish be-
tween plasminogen and active plasmin), was noted in
PCOS and control ovaries. Plasminogen/active plasmin
was predominantly present in the periphery of control
and PCOS ovaries. The plasminogen-specific antibody
was expressed throughout the control ovaries with
strong staining noted in the FF and also observed in the
GC and large follicles of both control and PCOS ovaries.
TC and small follicles of PCOS ovaries seem to express
plasminogen however this was not observed in controls.
Image analyses that quantified the plasminogen/active
plasmin or plasminogen only markers did not reveal any
significant differences in the overall ovarian expression
between PCOS and controls. This is novel data showing
plasminogen and/or plasmin expression in mice ovaries.
In humans, Ambekar et al noted that plasminogen was
degraded in the FF of the ovary in women with PCOS
[17]. While we had hypothesized that the differences in
staining between the plasminogen/active plasmin and
plasminogen only antibodies would reveal the activity of
plasmin only in the ovarian tissues, we noted overall
stronger ovarian staining with the latter when compared
to the former antibody. This may be related to differ-
ences in the activity of each antibody type to its antigen/
s of interest. We have therefore discussed the activity
and distribution of plasminogen and plasmin inter-
changeably/collectively. The differential expression of
the plasminogen specific antibody in the small follicles
and in TC of PCOS and control ovaries may also infer
differential proteolytic activities between the physio-
logical need and actions of normal ovaries and that of
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the pathological state in PCOS. This disparity in plas-
minogen expression between PCOS and control ovaries,
combined with differential PAI-1 ovarian localisation
and expression within developing follicles in the 2 ex-
perimental models, as was noted earlier, may be induced
by the androgen (DHT) excess in the PCOS model ver-
sus that of controls, and suggests androgens may be in-
volved, at least in part, in regulating expression of
ovarian fibrinolytic/proteolytic markers and the ovarian
plasminogen system.
Limitations of the current study include use of a PCOS
mouse model that does not display all features of the hu-
man condition, though no animal model has been devel-
oped to date which does. The long-term postnally
treated DHT PCOS mouse provides the best mouse
model for experimental studies of PCOS pathogenesis
through replicating extensive ovarian (irregular cycles/
acyclicity, oligo−/anovulation, multicystic ovaries, antral
follicle arrest, increased follicle atresia, reduced granu-
losa and increased TC layer thickness), endocrine (re-
duced progesterone and increased DHT) and metabolic
(obesity, adipocyte hypertrophy, dyslipidaemia and pres-
ence of steanosis) features of humans affected by the
syndrome [20]. Strengths of our study include a compre-
hensive and novel analysis of the plasminogen system in
control and PCOS mouse ovaries, with few or no previ-
ous studies undertaken in either animal PCOS models
or in human PCOS studies.
Conclusions
Overall our results demonstrate both the presence of
four of the five fibrinolytic/proteolytic markers assessed
and note some differential expression of the plasmino-
gen system in the functional mouse ovary and in PCOS.
PAI-1 was expressed throughout the PCOS ovary, unlike
the peripheral distribution observed in control ovaries
and plasminogen was present in the small follicles only
in PCOS ovaries but not in the small follicles of control
ovaries. This may infer an active role of the proteolytic/
fibrinolytic system markers in early ovarian function in-
cluding in follicular development processes and ovula-
tion as well as differential proteolytic outcomes when
compared to the pathological PCOS state. Our results
however do not show a statistically significant difference
between markers assessed in PCOS versus controls for
overall (whole) ovarian expression or in individual sized
follicles for PAI-1. These outcomes may be related to
the small sample size assessed and the stage of the ovu-
lation cycle of mice. The differential expression of PAI-1
and plasminogen only in PCOS and control ovaries as
well as observations of differential PAI-1 patterns as fol-
licles develop may indicate potential differences in pro-
teolytic actions/levels of these markers and further
support our earlier conclusions of a possible disparity in
underlying causes or effects between ovarian physio-
logical and pathological (PCOS) states. These outcomes
may be related to differential androgen (DHT) levels be-
tween the two experimental models and infer that an-
drogens may play a role in regulation of expression of
ovarian plasminogen system markers.
Further studies with larger samples sizes and evaluat-
ing these fibrinolytic/proteolytic markers at different
time-points of the oestrous cycle, particularly immedi-
ately preceding ovulation, may help to further clarify
physiological and any potential pathological roles of
these markers in the aberrant ovulation process and in
folliculogenesis in PCOS. Such studies may significantly
improve our understanding of this very complex condi-
tion as well as assist with treatment options for the fre-
quent infertility noted for women with this common
syndrome.
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